Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 36.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,428 shares of the company’s stock after selling 10,015 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $1,078,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Commonwealth Equity Services LLC boosted its holdings in Amphastar Pharmaceuticals by 37.2% in the third quarter. Commonwealth Equity Services LLC now owns 9,861 shares of the company’s stock valued at $454,000 after acquiring an additional 2,674 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at about $215,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Amphastar Pharmaceuticals by 20.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,436 shares of the company’s stock worth $434,000 after purchasing an additional 1,582 shares during the period. Mackenzie Financial Corp acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $258,000. Finally, Strs Ohio raised its holdings in Amphastar Pharmaceuticals by 23.2% in the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock valued at $855,000 after buying an additional 3,500 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 14,000 shares of company stock valued at $655,145 in the last three months. 27.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price target on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Stock Down 1.3 %

Amphastar Pharmaceuticals stock opened at $42.21 on Thursday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.06 and a 52 week high of $67.66. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 1.02 and a beta of 0.85. The company’s 50-day moving average price is $42.73 and its two-hundred day moving average price is $50.69. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The company had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. On average, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.41 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.